Completed PHASE3 INTERVENTIONAL 1-arm NCT01140217

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception (Simplify)

An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System

Sponsor: Watson Pharmaceuticals

Conditions Contraceptive Usage

Interventions Norethindrone Acetate

Updated 8 times since 2017 Last updated: Sep 13, 2013 Started: May 31, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Contraceptive Usage, this trial is completed. The trial is conducted by Watson Pharmaceuticals and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Watson Pharmaceuticals

Data source: Watson Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Aventura, United States , Birmingham, United States , Chandler, United States , Chapel Hill, United States , Chicago, United States , Cleveland, United States and 43 more locations